Introduction: ONWARD Medical's Ambitious Growth
ONWARD Medical, a pioneering neurotechnology firm based in Eindhoven, has successfully secured €40.6 million in funding through a private placement aimed at advancing its innovative spinal cord stimulation implants. Announced on April 16, 2026, this strategic funding round was strongly supported by EQT Life Sciences, leading the way with a €25 million investment.
Focus on the ARC-IM and ARC-EX Systems
The financial boost is primarily allocated towards enhancing ONWARD's investigational ARC-IM® system, which targets blood pressure instability in spinal cord injury patients. This cutting-edge implant delivers direct stimulation to the spinal cord, promising more effective treatments across various conditions – not just blood pressure issues but also bladder function and potential movement restoration when integrated with AI technology for brain-computer interfaces.
The Empower BP Trial: A Game Changer for Patients
Central to this funding is the Empower BP pivotal trial, which aims to validate the efficacy of ARC-IM® against serious blood pressure complications like orthostatic hypotension and autonomic dysreflexia – conditions that severely impact the quality of life for those with spinal injuries. Following FDA Investigational Device Exemption approval in August 2025, the trial is set to involve 20 leading neurological research centers across several countries, including the U.S. and key European nations.
Expanding the Reach: Commercialization of ARC-EX
The raise also supports expanding sales and commercial operations for the existing ARC-EX® system, an external, non-invasive solution already approved in the US and Europe. This system utilizes surface electrodes to stimulate the spinal cord and is pivotal in enhancing voluntary motor functions for patients recovering from spinal cord injuries.
Future Implications of ONWARD's Innovations
With RC-IM® and ARC-EX® advancing in clinical acceptance, ONWARD is positioned at the forefront of neurorehabilitation technology. The backing from EQT Life Sciences not only assures financial stability—extending the company's runway to Q1 2028—but also reflects confidence in the transformative potential of these medical devices.
Conclusion: A Step Toward a Neurotechnology Revolution
CEO Dave Marver echoed the significance of this funding round, highlighting how it underscores the trajectory of both ARC-IM® and ARC-EX®. As ONWARD navigates through these innovative advancements, the potential for improved treatment options for spinal cord injury patients is becoming increasingly tangible. The rest of the tech world watches closely, as these developments not only enhance patient lives but also redefine standards within the medical technology sphere.
Add Row
Add
Write A Comment